Management Articles

Bariatric surgery is an efficient method ? to achieve significant weight loss for NASH/NAFLD, learn more from our management articles.

NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Authors: Loomba R, Huang DQ, Sanyal AJ et al.
Published in Gut (March 2023)
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

NAFLD and New-Onset Heart Failure: What is the Link?

Authors: Inciardi RM, Mantovani A and Targher G
Published in Current Heart Failure Reports (July 2023)
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?

Adipose tissue insulin resistance and fibrosis stage in NASH

Authors: Kalavalapalli S, Leiva EG, Lomonaco R et al.
Published in Journal of Clinical Endocrinology and Metabolism (April 2023)
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
Read MoreAdipose tissue insulin resistance and fibrosis stage in NASH

Hepatic Macrophages in NAFLD: A Novel Therapeutic Target?

Authors: Vonderlin J, Chavakis T, Sieweke M et al.
Published in Cellular and Molecular Gastroenterology and Hepatology (March 2023)
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Read MoreHepatic Macrophages in NAFLD: A Novel Therapeutic Target?

MASLD: A New Fatty Liver Disease Nomenclature?

Authors: Rinella ME, Lazarus JV, Ratziu V et al.
Published in Journal of Hepatology (June 2023)
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Read MoreMASLD: A New Fatty Liver Disease Nomenclature?

Measuring NAFLD Models of Care: A New Strategic Framework?

Authors: Allen AM, Younossi ZM, Tsochatzis EA et al.
Published in Nature Reviews: Gastroenterology and Hepatology (June 2023)
Models of care (MoCs) establish comprehensive frameworks for the provision of healthcare services along a continuum of care.
Read MoreMeasuring NAFLD Models of Care: A New Strategic Framework?

Adverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?

Authors: Linge J, Nasr P, Sanyal AJ et al.
Published in JHEP Reports: Innovations in Hepatology (December 2022)
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
Read MoreAdverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?

NAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting Disparities

Authors: Shaheen M, Schrode KM, Tedlos M et al.
Published in Frontiers in Physiology (February 2023)
According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18% in 1988-1991 to an estimated 25-50% in recent years.
Read MoreNAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting Disparities

Clinical outcome prediction in NAFLD: comparing non-invasive tools and liver histology

Authors: Mózes FE, Lee JA, Vali Y et al.
Published in The Lancet Gastroenterology and Hepatology (June 2023)
Previous studies investigating non-invasive tools for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, have demonstrated the clear diagnostic efficacy of liver stiffness measurement by vibration-controlled transient elastography (LSM-VCTE).
Read MoreClinical outcome prediction in NAFLD: comparing non-invasive tools and liver histology

Anti-inflammatory and Antifibrotic Targets for the Treatment of NASH: a Review

Authors: Tacke F, Puengel T, Loomba R et al
Published in J Hepatol (April 2023)
Generally, NASH and fibrosis correlate with the development of cirrhosis and other negative clinical outcomes. Treatments often aim to target inflammation, fibrosis, cell injury or metabolic dysregulation.
Read MoreAnti-inflammatory and Antifibrotic Targets for the Treatment of NASH: a Review

Biomarker Qualification for NAFLD and NASH: Insights from the LITMUS Consortium

Authors: Rasmussen DGK, Anstee QM, Torstenson R et al.
Published in Journal of Hepatology (April 2023)
Interventional trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, are often limited by patient heterogeneity and, hence, response variability.
Read MoreBiomarker Qualification for NAFLD and NASH: Insights from the LITMUS Consortium

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES